Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920818 | 0.92 | HTR6 (0.40) | HTR6HRH1PTGDR2KDM4EKMT2A | |
| SCHEMBL6922091 | 0.91 | HTR6 (0.36) | HTR6HRH1ADRB2ADRB1ADRB3 | |
| SCHEMBL6920035 | 0.90 | HTR6 (0.37) | HTR6HRH1PTGDR2KDM4EKMT2A | |
| SCHEMBL15087610 | 0.90 | HTR6 (0.36) | HTR6HRH1ADRB2ADRB1ADRB3 | |
| SCHEMBL6922002 | 0.85 | HTR6 (0.37) | HTR6HRH1PTGDR2KDM4EKMT2A | |
| SCHEMBL16775014 | 0.84 | HTR6 (0.39) | HTR6HRH1MCHR1 | |
| SCHEMBL13834003 | 0.82 | HTR6 (0.39) | HTR6HRH1ADRB2ADRB1ADRB3 | |
| SCHEMBL6921457 | 0.82 | HTR6 (0.35) | HTR6PTGDR2MCHR1LMNA | |
| SCHEMBL6921538 | 0.82 | HTR6 (0.40) | HTR6HRH1PTGDR2KDM4EKMT2A | |
| SCHEMBL14729242 | 0.82 | HTR6 (0.38) | HTR6HRH1ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006234-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| WO-2011038164-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | HTR6 22/4885HRH1 10/4885ADRB2 243/4885 |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | HTR6 22/4885HRH1 10/4885ADRB2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.